High-density Lipid Cholesterol Research Articles

Taohong Siwu decoction ameliorates atherosclerosis in rats possibly through toll-like receptor 4/myeloid differentiation primary response protein 88/nuclear factor-κB signal pathway.

To investigate the effect of Taohong Siwu decoction (, TSD) on atherosclerosis in rats as well as investigate the underlying mechanism based on molecular docking. Sixty healthy male Sprague-Dawley rats were randomly divided into 6 groups with 10 rats in each group: control group, model group, atorvastatin group (AT, 2.0 mg/kg), and TSD groups (20, 10, 5 g/kg) after 7 d of acclimation. The model of atherosclerosis was successfully established except the control group by high fat diet (HFD) and vitamin D2. Biochemical analyzers were used to detect the levels of triglyceride (TG), total cholestero (TC), low density lipoprotein-cholesterol (LDL-C) and high density lipid-cholesterol (HDL-C) in blood lipid. The levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and interleukin-1β (IL-1β) were determined by enzyme-linked immunosorbent assay. Sudan IV staining and Hematoxylin and eosin staining (HE staining) were performed to observe the pathological changes in aortic tissue. Molecular docking technology was used to predict the best matching between the main components of TSD and the target proteins. The expression of target proteins was further detected by quantitative real time polymerase chain reaction (qRT-PCR) and Western blot analysis. The results showed that TSD restricted atherosclerosis development and decreased the inflammatory cytokines in plasma. Molecular docking results predicted that the main components of TSD showed a strong binding ability with toll-like receptor (TLR4), myeloid differentiation primary response protein 88 (MyD88), and nuclear factor kappa-B (NF-κB). The results of qRT-PCR and Western blot analysis showed that the mRNA and protein expressions of TLR4, MyD88 and NF-κB p65 in the aorta were reduced in atorvastatin group and TSD group. TSD can ameliorate atherosclerosis in rats, and the underlying mechanism is supposed be related to the suppression of inflammatory response by regulating TLR4/MyD88/NF-κB signal pathway.

Incorporating longitudinal history of risk factors into atherosclerotic cardiovascular disease risk prediction using deep learning

It is increasingly clear that longitudinal risk factor levels and trajectories are related to risk for atherosclerotic cardiovascular disease (ASCVD) above and beyond single measures. Currently used in clinical care, the Pooled Cohort Equations (PCE) are based on regression methods that predict ASCVD risk based on cross-sectional risk factor levels. Deep learning (DL) models have been developed to incorporate longitudinal data for risk prediction but its benefit for ASCVD risk prediction relative to the traditional Pooled Cohort Equations (PCE) remain unknown. Our study included 15,565 participants from four cardiovascular disease cohorts free of baseline ASCVD who were followed for adjudicated ASCVD. Ten-year ASCVD risk was calculated in the training set using our benchmark, the PCE, and a longitudinal DL model, Dynamic-DeepHit. Predictors included those incorporated in the PCE: sex, race, age, total cholesterol, high density lipid cholesterol, systolic and diastolic blood pressure, diabetes, hypertension treatment and smoking. The discrimination and calibration performance of the two models were evaluated in an overall hold-out testing dataset. Of the 15,565 participants in our dataset, 2170 (13.9%) developed ASCVD. The performance of the longitudinal DL model that incorporated 8 years of longitudinal risk factor data improved upon that of the PCE [AUROC: 0.815 (CI 0.782–0.844) vs 0.792 (CI 0.760–0.825)] and the net reclassification index was 0.385. The brier score for the DL model was 0.0514 compared with 0.0542 in the PCE. Incorporating longitudinal risk factors in ASCVD risk prediction using DL can improve model discrimination and calibration.

No evidence for a diminished ovarian reserve among patients with hypertensive disorders of pregnancy: a case control study

BackgroundExisting evidence suggests a relation between cardiovascular dysfunction and diminished ovarian reserve. While it is known that pre-existent cardiovascular dysfunction is also associated with the development of preeclampsia (PE) during pregnancy, we hypothesize that signs of diminished ovarian reserve may occur more frequently among women with a history of hypertensive disorders of pregnancy (HDP). The aim of our study was therefore to analyse if women with a history of HDP show signs of diminished ovarian reserve, represented by lower anti-Mullarian hormone (AMH) levels, compared to controls. For this retrospective observational case control study, patients included women with a history of HDP, whereas controls constituted of women with a history of an uncomplicated pregnancy. The study was conducted in a tertiary referral centre in which all women underwent a one-time cardiovascular and metabolic assessment. Ovarian reserve and markers of cardiovascular function were evaluated, adjusted for age and body mass index (BMI) using linear regression analyses.Results163 patients and 81 controls were included over a time span of 3 years. No signs of diminished ovarian reserve i.e. lower AMH level were observed in the patient group versus controls. A subgroup analysis even showed higher AMH levels in late onset HDP as compared to controls (2.8 vs. 2.0 µg/L, p = 0.025). As expected, cardiovascular function markers were significantly less favourable in the patient group compared to controls; higher levels of systolic blood pressure (BP) (5%), diastolic BP (4%), triglycerides (29%), glucose (4%) and insulin levels (81%) (all p < 0.05), whereas high density lipid (HDL) cholesterol was 12% lower (NS).ConclusionsDespite unfavourable cardiovascular risk profile, the present study does not substantiate the hypothesis that women with HDP show accelerated ovarian ageing as compared to healthy parous controls. Although HDP patients should be warned about their cardiovascular health, they shouldn’t be concerned about unfavourable ovarian reserve status.

Serum lipid reference values recommended during a twin pregnancy and evaluating its association with perinatal outcomes

BackgroundMaternal lipid metabolism fluctuations have been shown to increase the risk of adverse pregnancy outcomes. However, there is no consensus over what constitutes normal maternal lipid values during twin pregnancy. Therefore, the aim of this study was to establish a serum lipid reference range for a twin pregnancy.MethodsA retrospective survey was conducted, from 2011 to 2021, at the Peking University Third Hospital. A total of 881 twin pregnancies, with lipid data from early and middle pregnancies, were included. After excluding those with adverse pregnancy outcomes, we performed a descriptive analysis of total cholesterol (TC), triglycerides (TG), high-density lipid cholesterol (HDL-C), and low-density lipid cholesterol (LDL-C) levels, using the mean and standard deviation to determine appropriate percentiles. We later determined the lipid reference range in early and middle pregnancy based on the initial results. We evaluated Inappropriate lipid levels associations with pregnancy outcomes, including gestational diabetes, pregnancy-induced hypertension, small for gestational age.Results(1) Serum levels of TC, TG, LDL-C, and HDL-C increased significantly from early to late pregnancy, where the greatest increase was observed in TG. (2) Based on the results, we recommend that TC, TG, and LDL-C serum reference values during early and middle pregnancy should be less than the 95th percentile. On the other hand, HDL-C should be greater than the 5th percentile. During early pregnancy, the values recommended are TC < 5.31 mmol/L, TG < 2.25 mmol/L, HDL > 1.02 mmol/L and LDL < 3.27 mmol/L, and those during middle pregnancy are TC < 8.74 mmol/L, TG < 4.89 mmol/L, HDL > 1.25 mmol/L and LDL < 5.49 mmol/L, while the values during late pregnancy are TC < 9.11 mmol/L, TG < 6.70 mmol/L, HDL > 1.10 mmol/L and LDL < 5.81 mmol/L. Higher levels of blood lipids were associated with GDM, PE, SGA.ConclusionsWe suggested a reference ranges for blood lipids during the twin pregnancy in a Chinese population. The reference ranges recommended by this study can be used to identify women with twin pregnancies using unfavorable lipid values. Higher levels of blood lipids were associated with adverse pregnancy outcomes.

Association between cardiometabolic index and erectile dysfunction among US adults: a cross-sectional analysis of the National Health and Nutrition Examination Survey 2001-2004.

The aim of this study was to assess the association between a new metabolic index, the cardiometabolic index (CMI) and erectile dysfunction (ED). The data for this study relied on the National Health and Nutrition Examination Survey (NHANES), a cross-sectional database, between 2001 and 2004. The CMI was calculated as the following formula: Triglyceride (TG) (mmol/L)/ High density lipid-cholesterol (HDL-C) (mmol/L) ×waist-height ratio (WHtR). The multivariate logistic regression analyses were conducted to assess the association between CMI and ED, supplemented by subgroup analysis and dose-response curves. Finally, a total of 1367 adult male participants were identified, and the mean CMI was 0.83 ± 0.02. Multivariate logistic regression analysis showed that in model 2 controlling for all potential confounders, CMI was significantly associated with ED (OR = 1.49, 95% CI: 1.09, 2.04) (p = 0.017). Subsequently, we convert the CMI from a continuous variable to a categorical variable (Tertiles). The results showed that male participants in CMI Tertile 3 group had a higher risk of ED than those in Tertile 1 group in model 2 (OR = 2.07, 95% CI: 1.12, 3.83, P = 0.024). The subgroup analysis of model 2 demonstrated that CMI was significantly associate with ED in participants aged ≥50 y (OR = 2.31, 95% CI: 1.35, 3.95, P = 0.005), body mass index (BMI) > 30 kg/m2 (OR = 1.78, 95% CI: 1.10, 2.90, P = 0.023), with hypertension (OR = 1.89, 95% CI: 1.63, 3.45, P = 0.020), with diabetes mellitus (OR = 1.67, 95% CI: 1.13, 2.47, P = 0.015), with cardiovascular disease (CVD) (OR = 1.54, 95% CI: 1.12, 2.10, P = 0.011) and smoking (OR = 2.07, 95% CI: 1.26, 3.39, P = 0.007). This study demonstrates a strong association between CMI and ED and an increased risk of ED with higher CMI levels. More prospective studies with large samples and good designs are needed to validate our results in the future.

Abstract 14621: High-Density Lipoprotein Lipid and Protein Cargo and Cholesterol Efflux Capacity Before and After Bariatric Surgery

Introduction: Cholesterol efflux capacity (CEC) is inversely associated with incident CV events, independent of HDL-C. Obesity is characterized by low HDL-C and impaired HDL function. Bariatric surgery, including Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG), improves CV risk, but we have shown that the impact on CEC may differ by procedure over time post-op. Hypothesis: We hypothesized that RYGB and SG significantly affect HDL protein/lipid cargo and mediate CEC. Methods: We prospectively studied severely obese, nondiabetic women undergoing RYGB (n=31) or SG (n=36) before and at 6 and 12 months after surgery. Statistical analyses included Wilcoxon tests of log fold change in HDL proteins/lipids, hierarchical clustering to identify HDL protein/lipid clusters, and network mediation tests to identify cargo associated with CEC changes. Results: Subjects experienced similar weight loss regardless of procedure (38.0±10.4 kg at 12mo). Concentrations of 40 proteins (11 up, 29 down) and 95 lipids (46 up, 49 down) in HDL changed significantly following bariatric surgery. Proteins and lipids clustered into 9 and 14 groups of similar post-operative trajectories, respectively (Figure A). All clusters, other than 2 lipid clusters, showed similar responses regardless of procedure (Figure B). Despite similarities in cargo, changes in CEC differed depending upon time point and efflux pathway (Figure C). Network mediation analyses suggested that changes in 4 protein and 2 lipid clusters associated with post-operative changes in ABCA1-mediated CEC and changes in 1 lipid cluster associated with changes in non-ABCA1-mediated CEC (Figure D). Conclusions: In conjunction with substantial weight loss, bariatric surgery results in altered HDL protein/lipid cargo and CEC, possibly mediated by distinct HDL cargo. Further study of the mechanisms influencing HDL cargo in obesity and after bariatric surgery may lead to better understanding of CEC and management of CVD.

Predictive Value of Glycemic Variability and HDL-C for Secondary Persistent Inflammatory Immunosuppressed Catabolic Syndrome in Patients with Sepsis.

Sepsis patients with persistent inflammation, immunosuppression, and catabolism syndrome (PICS) have a poor prognosis, and early detection of biomarkers to predict its prognosis is particularly important. The purpose of this study is to investigate the predictive value of glycemic variability (GV) and high density lipid-cholesterol (HDL-C) for secondary PICS in patients with sepsis. One hundred and sixty-five patients with sepsis were enrolled in the retrospective study and divided into sepsis secondary PICS and non-PICS group. The daily blood glucose levels from 1 to 7 days after the diagnosis of sepsis were recorded, and GV was calculated. Logistic regression was used to analyze the risk factors of sepsis with PICS, receiver operating characteristic (ROC) curve was drawn to evaluate the predictive value of GV, and HDL-C for the prognosis of sepsis with PICS. In a study of 165 patients, PICS group tended to have higher GV and lower HDL-C levels than those in the non-PICS group. Logistic regression analysis identified GV and HDL-C as independent risk factors for the secondary PICS of sepsis. The results of ROC curve showed that GV and HDL-C had a certain predictive value for the secondary PICS of sepsis, the sensitivity of GV was 77.5%, specificity of 81.8%, the sensitivity of HDL-C was 76.6%, and specificity of 74.8%. GV and HDL are risk factors for PICS secondary to sepsis and have predictive value for patients' prognosis.

#5729 HIGHER DAILY PROTEIN INTAKE CAN IMPROVE THE GRAFT FUNCTION OF KIDNEY TRANSPLANT RECIPIENTS IN THE EARLY POSTTRANSPLANT PERIOD

Abstract Background and Aims Protein-energy wasting (PEW) is commonly seen among uremic patients, which may still exist after they received kidney transplantation,[1,2] and it is a determining factor in the progression of chronic kidney disease (CKD).[3] The use of immunosuppressants and glucocorticoids after transplantation will also affect the patients' metabolism and aggravate their malnutrition.[4,5] Adequate daily protein intake (DPI) in the early posttransplant period facilitates the rapid recovery of surgical wounds.[6] However, few studies focused on the impact of DPI on the early recovery of graft function. This study aimed to explore the relationship between DPI and graft function at month 3 posttransplant, which may provide a basis for clinical nutritional regimen of kidney transplant recipients. Method This is a retrospective observational study. 176 kidney transplant recipients (KTRs) who underwent kidney transplant in West China Hospital from December 2021 to June 2022 were included and followed up regularly. 24-hour urine urea data were collected at month 3 posttransplant to calculate their DPI. These KTRs were further divided into two groups according to the recommended DPI for KTRs by the 2021 Practice Guidelines for the Nutritional Management of Chronic Kidney Disease,[7] namely high intake group (Group 1, with DPI ≥ 1.4g/kg·d, n = 66) and low intake group (Group 2, with DPI &amp;lt; 1.4g/kg·d, n = 110). Laboratory data and posttransplant adverse events within 3 months were recorded. Multiple logistic regression was used to analyze the relationship between DPI and early posttransplant graft function. Results Mean DPI levels at month 3 posttransplant were 1.75±0.56 g/kg·d in Group 1 and 0.98±0.24 g/kg·d in Group 2, respectively. There was no significant difference in age, gender, pretransplant body mass index (BMI), dialysis type and time, donor type, or the ratio of delayed graft function (DGF) between the two groups. The levels of estimated glomerular filtration rate (eGFR), body mass index(BMI), hemoglobin (Hb), high-density lipid-cholesterol (HDL), and urinary protein at month 3 posttransplant in Group 1 were significantly higher than those in Group 2 (P &amp;lt; 0.005, Fig. 1). No statistical difference was found in the incidence of adverse events between the two groups at month 3 posttransplant. The results of multiple logistic regression analysis showed that higher DPI in the early posttransplant period was a protective factor for graft function after kidney transplantation. Conclusion In the early posttransplant period, higher dietary protein intake (DPI ≥ 1.4 g/kg·d) may improve graft kidney function, lipid metabolism, and renal anemia.

Cardiometabolic index is associated with urinary albumin excretion and renal function in aged person over 60: Data from NHANES 2011–2018

PurposeCardiometabolic index (CMI) is recently considered to have certain significance in the screening of diabetes, atherosclerosis, and renal dysfunction. Therefore, this study intends to explore the relationship between CMI and the risk of albuminuria. MethodsThis is a cross-sectional study involving 2732 elderly people (age ≥ 60). The research data are from the National Health and Nutrition Examination Survey (NHANES) from 2011 to 2018. Calculate CMI index: Triglyceride (TG) (mmol/L)/ High density lipid-cholesterol (HDLC) (mmol/L) × WHtR. ResultsThe CMI level in microalbuminuria group was significantly higher than that in normal albuminuria group (P < 0.05 or P < 0.01), whether in the general population or in diabetes and hypertensive population respectively. The proportion of abnormal microalbuminuria increased gradually with the increase of CMI tertile interval (P < 0.01). Correlation analysis showed that CMI was positively correlated with urinary albumin-creatinine ratio (UACR), blood urea nitrogen (BUN), and serum creatinine (Scr), and negatively correlated with estimated glomerular filtration rate (eGFR). With the occurrence of albuminuria as the dependent variable, weighted logistic regression analysis showed that CMI was an independent risk factor for microalbuminuria. Weighted smooth curve fitting showed that CMI index was linearly related to the risk of microalbuminuria. Subgroup analysis and interaction test showed that they participated in this positive correlation. ConclusionsObviously, CMI is independently associated with microalbuminuria, suggesting that CMI, a simple indicator, can be used for risk assessment of microalbuminuria, especially in diabetes patients.

Cardiometabolic profiles in children and adults with overweight and obesity and down syndrome.

Individuals with Down syndrome (DS) are at increased risk for being overweight/obese, but the associated cardiometabolic risk (CR) is not clear. Cross-sectional anthropometric and clinical laboratory data from a multi-site, international cohort of individuals with DS were analyzed to determine cardiometabolic risk by reporting observed distributions of cardiometabolic biomarkers in overweight/obese individuals with DS throughout the lifespan. Descriptive statistics and regression analyses by age categories determined the distributive percentiles for cardiometabolic biomarkers and tested for adiposity as a predictor of CR. Across seven DS clinics, data were collected on 240 patients between the ages of 3 and 63 years, with one quarter overweight and three quarters obese among children and nearly all adults being obese. In children and adults, most cardiometabolic biomarker profiles showed distributive values within normal ranges. Blood lipids were positively associated with body mass index (BMI) in children (high density lipid-cholesterol, p= 0.01; low density lipid-cholesterol, p= 0.02). Levels of hs-CRP were elevated in both children and adults, with BMI positively associated with hs-CRP in adults with DS (p= 0.04). Liver enzyme values were positively associated with BMI in children and adults. The data suggest that in contrast to the general population, in individuals with Down syndrome, being overweight and obese does not appear to confer a significantly increased risk for cardiometabolic disease by biomarker profile. Individuals with DS who are overweight/obese appear to have unique cardiometabolic profiles unrelated to adiposity, notable for increased hs-CRP and normal HA1c levels.

Correlation between Smoking and Dyslipidemia in Elderly Males: An Analytical Cross-Sectional Study

Aim: To investigate the association between smoking and dyslipidemia in elderly males while accounting for age, BMI, and alcohol use. Study design: Analytical cross-sectional study Place and Duration: This study was conducted at Bhitai Dental and Medical College Mirpurkhas from march 2021 to march 2022 Methodology: The research comprised 2,160 participants who were divided into 3 different groups: current smokers, non-smokers, &amp; past smokers. The research excluded those who smoked just sometimes (one cigarette per day). This study separated smokers into four categories: light (26.7 pack-years), medium (426.7-90.5 pack-years), heavy (440.5-75.5 pack-years), and extremely heavy (455.5-165.5 pack-years).On the same day, a survey, physical examination, and laboratory study of blood samples were used to evaluate the study population. The person was assessed while wearing light clothes and no shoes, and anthropometric measures comprised height and body weight. Weight was divided by height squared (kg/m2) to get the BMI. Using established protocols in the clinical laboratory, an automated biochemistry analyzer measured the blood levels of total cholesterol, triglycerides, high-density lipid cholesterol, low- density lipid cholesterol, Apo protein B, and Lipoprotein. Result: When compared to present smokers, the levels of triglycerides and high-density lipid cholesterol among non-smokers and former smokers were statistically significantly different (P=0.001). Other variables, such as Age, body mass index, use of liquor, systolic and diastolic blood pressure, did not significantly differ between non-, past, and present smokers. In comparison to light smokers, moderate, heavy, and very heavy smokers more commonly displayed abnormal levels of TGs, Apo-B, and TC, while very heavy smokers less frequently displayed abnormal levels of low-density lipid cholesterol. It was unexpected to find that among very heavy smokers, aberrant Apo-B levels were seen more frequently than low-density lipid cholesterol levels. The prevalence of abnormal HDL-C and lipoprotein (a) was higher among light smokers. After accounting for alcohol, BMI, and age, smoking remained a significant independent threat fact for dyslipidemia (P = 0.032). Conclusion:The study revealed that smoking caused TGs and apoB levels to rise in elderly males, and HDL-C levels to decrease, making it an independent risk factor for dyslipidemia. Keywords: smoking, dyslipidemia, elderly, males

Anti-Obesity Effect of Carom Seeds (Trachyspermum Ammi) Tea on Bmi and Lipid Profile Leading to Cardiovascular Diseases

Introduction: Obesity refers to the deposition of fat ratio in the fat tissues of muscles in which the BMI raised (obesity and hyperlipidemia) that may have a negative impact on health. Herbs from ancient times till today have been utilized as a solution for some infections and issues. Objectives: The purpose of this research was to evaluate the defensive impact of Carom seed (Trachyspermum ammi) against obesity and hyperlipidemia. Materials &amp; Methods: Carom seed was acquired from the Faisalabad and was washed to expel the soil, dust, and outside materials clung to the test surface. The crude material was dried by utilizing an air forced draft oven. After planning, it was stuffed in water/airproof plastic containers and put away at 5 ± 1 °C until further analysis. Moreover, the blood samples were collected on 0-day, 15-day, 30-day, and 60-day by taking 15ml venous blood after a 12-hour night of fasting. Serum samples were separated by centrifugation and stored at -70?c until analysis. Low-density lipoprotein and high-density lipoprotein cholesterol were measured enzymatically. Concentrations of triglycerides and total cholesterol were measured by Peridochrom Triglyceride Kits. Sixteen subjects, separated into four groups were given carom seeds in the form of tea i.e. G0 (Control), G1 (500mg), G2 (1 mg) and G3 (1.5 mg) individually. This was an eight-week trial and all the parameters e.g. Body Mass Index, High-Density Lipid, Low-Density Lipid, Tri-Glycerides, and Total Cholesterol were measured at 0 days, 15 days, 30 days, and 60 days respectively. The yield data of carom seed tea for anti-obesity and anti-hyper-lipidemic effects obtained for each treatment were subjected to a paired t-test by using SPSS. Results: The significant change has been observed between the groups with the relevance of treatments given. G0 showed no significant changes among all the groups while G2 and G3 reported considerable changes because of the dosage concentrations of carom seed tea i.e. 1g and 1.5g respectively (p&lt;0.05).

O-182 No higher prevalence of metabolic dysfunction among subfertile women in an urban population

Abstract Study question What is the prevalence of metabolic dysfunction, like insulin resistance, hyperglycaemia, hypertension, and/or dyslipidaemia, among subfertile women compared to healthy controls? Summary answer Signs of metabolic dysfunction were not observed more frequently in subfertile women than in controls. Overweight and obese patients were at risk for metabolic dysfunction. What is known already Metabolic dysfunction is known to impair female fecundity as it is linked to a longer time-to-pregnancy and to subfertility. Three times as many PCOS patients are diagnosed with metabolic syndrome than age matched controls. Moreover, a recent study showed a higher prevalence among the entire subfertile population. Metabolic disorders have been connected to the impairment of normal ovarian function and pituitary-hypothalamic axis. Obesity is correlated with menstrual irregularities, ovulation disorders and infertility. On top, it can increase risk of miscarriage and reduce chances with assisted reproductive technologies. Therefore, metabolic dysfunction might also be a driving factor behind unexplained subfertility. Study design, size, duration This cross-sectional observational case control study was performed in a secondary and tertiary care fertility clinic (MUMC+, Maastricht, The Netherlands). Patients were referred to the fertility clinic with either primary or secondary subfertility (inability to conceive after one year of regular unprotected intercourse), controls were healthy, parous women. All participants were aged between 18 and 41 years at time of inclusion. 119 patients and 68 controls were included over a time span of 3 years. Participants/materials, setting, methods A basic medical history was collected using questionnaires. Physical examination included measurement of weight, height, waist and hip circumference, blood pressure and pulse. Venipuncture was performed after an overnight fast on cycle day 2-4; including insulin, glucose, triglycerides, high-density lipid cholesterol, total cholesterol, glomerular filtration rate, urea, uric acid, creatinine, follicle stimulating hormone, estradiol and anti-Mullarian hormone. Urine was collected to measure protein and creatinine. Metabolic syndrome was diagnosed according to Adult Treatment Panel-III guidelines. Main results and the role of chance Body weight and BMI were similarly distributed between patients and controls. Main causes of subfertility comprised male factor (12%), anovulation (20%) and unexplained subfertility (47%). Comparing patients to controls, unexplained subfertility only had slightly higher HDL cholesterol levels (p = 0.046). Anovulatory patients showed 2% higher glucose (p = 0.003) and 133% higher AMH levels (p &amp;lt; 0.001). Metabolic syndrome was diagnosed in 6% of unexplained subfertility patients, in 4% of male factor patients and in 5% of anovulatory patients. No controls were diagnosed with metabolic syndrome. In a comparison of overweight and obese patients to normal weight patients we observed resp. 16% and 37% higher waist circumference (p &amp;lt; 0.001), 7% and 11% higher waist-to-hip ratio (p &amp;lt; 0.01), 37% and 197% higher fasting insulin (p &amp;lt; 0.01), 30% and 198% higher HOMA-IR (p &amp;lt; 0.02) and 8% and 24% higher uric acid levels (p &amp;lt; 0.03). Concomitantly, obese patients showed dyslipidemia with 98% higher triglyceride levels (p &amp;lt; 0.001) and 24% lower HDL cholesterol (p &amp;lt; 0.01). 181% higher AMH levels were found in obese patients (p &amp;lt; 0.01). Metabolic syndrome was diagnosed in 1% of normal weight patients, 4% of overweight patients and in 25% of obese patients. Limitations, reasons for caution Participants were young and remarkably healthy, which might account for the low prevalence of metabolic disorders. It is known that the prevalence of metabolic dysfunction is strongly dependent on socioeconomic and geographic determinants in various populations. Our findings apply to a largely ethnically homogeneous Caucasian female population in the Netherlands. Wider implications of the findings We found that the presence or specific cause of subfertility per se, cannot be regarded as a reliable and strong predictor of metabolic dysfunction, even in anovulatory subfertility. As can be expected, metabolic dysfunction is highly associated with BMI and obese patients should consider lifestyle intervention to prevent future complications. Trial registration number Not applicable

A Class Effect Network Meta-analysis of Lipid Modulation in Non-alcoholic Steatohepatitis for Dyslipidemia.

Pharmaceutical therapy for NASH is associated with lipid modulation, but the consensus on drug treatment is limited and lacks comparative analysis of effectiveness. A network meta-analysis was conducted to compare NASH drug classes in lipid modulation. Online databases were searched for randomized controlled trails (RCTs) evaluating NASH treatments in biopsy-proven NASH patients. Treatments were classified into four groups: (1) inflammation, (2) energy, (3) bile acids, and (4) fibrosis based on the mechanism of action. A Bayesian network analysis was conducted with outcome measured by mean difference (MD) with credible intervals (Crl) and surface under the cumulative ranking curve (SUCRA). Forty-four RCTs were included in the analysis. Bile acid modulating treatments (MD: 0.05, Crl: 0.03-0.07) were the best treatment for improvement in high-density lipid (HDL) cholesterol, followed by treatments modulating energy (MD: 0.03, Crl: 0.02-0.04) and fibrosis (MD: 0.01, Crl: -0.12 to 0.14) compared with placebo. The top three treatments for reduction in triglycerides were treatments modulating energy (MD: -0.46, Crl: -0.49 to -0.43), bile acids (MD: -0.22, Crl: -0.35 to -0.09), and inflammation (MD: -0.08, Crl: -0.13 to -0.03) compared with placebo. SUCRA found treatment modulating fibrosis (MD: -1.27, Crl: -1.76 to -0.79) was the best treatment for reduction in low-density lipid (LDL) cholesterol followed by treatment modulating inflammation (MD: -1.03, Crl: -1.09 to -0.97) and energy (MD: -0.37, Crl: -0.39 to -0.34) compared with placebo, but LDL cholesterol was worsened by treatments modulating bile acids. Network analysis comparing the class effects of dyslipidemia modulation in NASH found that treatment targets can include optimization of atherogenic dyslipidemia. Future studies are required to evaluate the cardiovascular outcomes.

Association between Serum Lipid Parameters and Cognitive Performance in Older Adults.

(1) Background: Previous studies have suggested the association between lipid profiles and cognitive function in older adults. However, they generated inconsistent results. We aim to determine the relationship between lipid profiles and cognitive performance in older adults. (2) Methods: We used the 2011–2014 National Health and Nutrition Examination Survey. This study included 2215 participants who were aged more than 60 years old and free of coronary heart disease or stroke. Lipid profiles included total cholesterol (TC), low density lipid cholesterol (LDL), high density lipid cholesterol (HDL), and triglyceride (TG). Cognitive function was assessed using the digit symbol substitution test (DSST). (3) Results: Positive correlations of DSST were observed with TC (r = 0.111; p < 0.0001), HDL (r = 0.127; p < 0.0001), and LDL (r = 0.107; p = 0.0005). However, there was no significant relationship between TG and DSST. A one-unit increase in HDL was associated with an increase in DSST score (beta coefficient: 0.036; p = 0.018); but the association was not significant for LDL, TG, and TC. In the categorical analysis, the high HDL group had a higher DSST score than the low HDL group (beta = 3.113; p < 0.0001) and the low TG group was more likely to show a lower DSST score than the high TC group (beta = −1.837; p = 0.0461). However, LDL and TC showed no statistically significant associations. Moreover, HDL was only associated with a 0.701 times increased risk of cognitive impairment (95% CI = 0.523–0.938) in the logistic regression analysis. (4) Conclusions: Higher blood concentrations of HDL levels were positively associated with DSST scores in older adults. We suggest that the high levels of HDL may be a protective factor against cognitive impairment.

Development of a Prognostic Model for Stump Healing in Major Lower Limb Amputation among the Diabetic Population

Background: This study aimed to explore the effect of haematological markers as well as patient characteristics on stump healing in patients who underwent a lower limb amputation procedure. In addition, a practical model regarding factors that affected stump healing was developed. Methods: Patients who underwent a major lower limb amputation (above knee and below knee) at the Royal Infirmary of Edinburgh from the period of 2007 to 2010 were included in this study. A prognostic model utilizing backward stepwise logistical regression was developed to measure the probability of lower limb stump healing. The relationship between the dependent and independent variables was identified using univariate and multivariate logistic regression. Results: Three variables, namely serum sodium, serum creatinine and serum high density lipid cholesterol were identified which influenced stump healing. Patients with normal serum sodium were 75% more likely to have lower limb stump healing compared to that of patients with abnormal serum sodium (odds ratio [OR] 1.756; 95% confidence interval [CI] 1.048–2.942). Patients with normal serum creatinine were 66% more likely to have their stump healed (OR 1.664; 95% CI 0.94 to 2.946). The healing rate of patients with a normal level of serum high density lipid cholesterol was 75%, in contrast to patients with an aberrant level of serum high density lipids cholesterol (OR 1.753; 95% CI 1.061 to 2.895). The effectiveness of the retrospective stump-healing model was demonstrated by the area under the ROC curve (0.612), which was supported by the Hosmer and Lemeshow goodness-of-fit test (p = 0.879). Conclusions: Serum sodium, serum high density lipid cholesterol and serum creatinine have a strong correlation with lower limb stump healing. However, serum sodium and serum high density lipid cholesterol secondary to multiple co-morbidities in this cohort group could be altered secondary to disease pathology itself.

Efficacy of simvastatin on carotid atherosclerotic plaque and its effects on serum inflammatory factors and cardiocerebrovascular events in elderly patients.

To investigate the efficacy of simvastatin on carotid atherosclerotic plaque (CAP) and its effects on serum inflammatory factors and cardiocerebrovascular events in elderly patients, 130 elderly patients with CAP were randomly divided into observation (n=65) and control groups (n=65). The control group was treated with 75 mg/day aspirin enteric-coated tablets, and the observation group was administered additional 20 mg/day simvastatin. Serum total cholesterol, triglyceride, and high- and low-density lipoprotein cholesterol levels (evaluated via the endpoint method) were determined in both groups. Furthermore, the length, thickness and number of CAPs was measured using color Doppler ultrasonography. In addition, levels of inflammatory biomarkers including high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), nitric oxide, D-dimer and fibrinogen, as well as change in microemboli count, were also compared After treatment, the observation group exhibited a significant reduction in size, thickness, and number of CAP and intima-media thickness compared with before treatment. However, no significant difference was found in the indicators of CAPs in the control group before and after treatment. The levels of total cholesterol, triglyceride, and low-density lipid cholesterol decreased, while high-density lipid cholesterol increased in the observation group after treatment, with notable changes in the observation group compared with in the control group. Overall response rate was higher in the observation group compared with the control group. TNF-α, IL-6, and hs-CRP levels in the observation group decreased after treatment compared with those before treatment and those in the control group. Furthermore, the rate of microemboli positivity was lower in the observation group than in the control group. Moreover, the overall incidence of acute cardiocerebrovascular events was lower in the observation group than in the control group. Therefore, it was demonstrated that simvastatin can reduce blood lipid levels, decrease the quantity and size of plaques, alleviate inflammatory response, reduce microemboli formation and reduce the risk of cardiocerebrovascular events in elderly patients with CAP.

Independent Effects of Metabolic Syndrome and Air Pollution (PM2.5) on Atherosclerosis in Modernizing China

Background: Air Pollution (AP) and metabolic syndrome (MS) are important global health hazards of the 21st century, in mainland China in particular, and AP has been associated with increased prevalence of cardiovascular diseases, and stroke. Methods: To evaluate the impact of metabolic syndrome on AP-related atherogenesis, 1557 Han Chinese adults (mean age 47.2±11.8 years, male 47%) in Hong Kong, Macau, Pun Yu, Yu County (Shanxi coalmine) and 3-Gorges (Yangtze River) were studied. Cardiovascular risk profiles and metabolic syndrome (IDF criteria) were evaluated. PM2.5 (satellite sensor modeling), and atherosclerotic surrogates, brachial reactivity (FMD) and carotid Intima-media thickness (IMT) (ultrasound), were measured. Results: The yearly PM2.5 concentration ranged from 34.0μg/m³ in Hong Kong to 93.8μg/m³ in 3-Gorges Territories. MS was diagnosed in 340 subjects (21.8%). Smoking status, gender and PM2.5 were similar in the MS cohort versus those without MS. Blood pressures (SBP and DBP), waist circumference, triglycerides and glucose were higher, but high-density lipidcholesterol was lower in the MS cohort, compared to the other subjects. Brachial FMD was significantly lower and carotid IMT significantly higher (0.70±0.13 mm, 95% CI 0.68-0.71 mm vs. 0.63mm±0.14mm, 95% CI 0.62-0.64 mm) in the MS cohort than those without (P&lt;0.0001). On multivariate regression, PM2.5 was not related to MS development, but was significantly related to carotid IMT in both no MS (beta=0.234, P&lt;0.0001) and MS cohorts (beta=0.245, p&lt;0.0001), independent of age, SBP, and waist circumference. There was no direct interaction between PM2.5 and MS. Conclusions: Both AP and MS have independent impacts on atherogenic processes in China, with significant implications for atherosclerosis prevention.

Is the effect of atorvastatin 60 mg on stabilization of lipid-rich plaque equivalent to that of rosuvastatin 10 mg? A serial optical coherence tomography combined with intravascular ultrasound imaging.

This study aimed to compare the effect of atorvastatin 60 (AT60) mg to that of rosuvastatin 10 (RT10) mg on the morphological changes in lipid-rich plaques (LRPs) and plaque volume, using serial optical coherence tomography (OCT) and intravascular ultrasound imaging (IVUS). Intensive lipid lowering therapy by statin provides more clinical benefit compared to that of moderate lipid lowering therapy. Fifty patients who underwent OCT and IVUS at baseline, 6, and 12 months were grouped by statin therapy into the AT60 mg (n = 27) and RT10 mg (n = 23) groups. The relationships between absolute and percentage changes in biomarkers and fibrous cap thickness (FCT) during follow-up were investigated using a simple regression analysis. At 6 months, the mean low-density lipoprotein cholesterol level reduced from 113.5 to 65.5 mg/dl (AT60 mg group) and 100.2 to 72.2 mg/dl (RT10 mg groups). A continuous increase in FCT from baseline to 12 months was observed in both groups (p < .001, p < .001, respectively). Mean lipid arc significantly decreased in both AT60 mg (189.0 ± 55.9°, 170.9 ± 60.2°, 155.6 ± 50.6°, p < .001) and RT10 mg (160.0 ± 45.6°, 151.2 ± 48.5°, 141.1 ± 52.9°, p = .010) groups. Plaque burden did not change significantly in both groups. Lipid-lowering therapy effect with AT60 mg was equivalent to that of RT10 mg in terms of change in plaque morphology. AT60 mg showed more intensive low-density lipid cholesterol level reduction compared to RT10 mg while RT10 mg was effective in increasing the high-density lipid cholesterol level. Both statin therapies could effectively stabilize LRPs.

Rosuvastatin and Fenofibrate Combination in The Treatment of Mixed Hyperlipidemia: A Narrative Review

Introduction: Patients with mixed dyslipidemia are presented with high levels of low-density lipid cholesterol (LDL-C), triglycerides (TG), and reduced high-density lipid cholesterol (HDL-C). Though useful in lowering LDL-C, therapy with rosuvastatin is insufficient in optimizing the overall lipid profile, thus putting the patient at risk of residual cardiovascular risk. A combination of statin with other lipid-modifying agents has been used with more efficient lipid control and cardiovascular risk prevention. Of these, fenofibric acid is the most frequently used, along with rosuvastatin.&#x0D; Methods: Authors conducted a literature search of published literature to assess the use of rosuvastatin and fenofibrate combination in the management of mixed hyperlipidaemia.&#x0D; Results and discussion: The authors selected a total of 46 articles to be included in the review. Due to the small number of articles and heterogeneity on the combination of rosuvastatin and fenofibrate combination in mixed hyperlipidemia, the findings herein are presented using narrative summaries. Based on the thorough assessment of the selected literature, the essential themes that emerged from the review include safety and efficacy of rosuvastatin and fenofibrate combination, place of therapy of rosuvastatin, and fenofibrate combination, and potential cardiovascular risk reduction with rosuvastatin and fenofibrate combination. &#x0D; Conclusion: Based on the review, the authors suggested that the combination therapy with fenofibric acid was beneficial, well-tolerated with a similar safety profile compared with statin monotherapy. The combination therapy of moderate dose rosuvastatin and fenofibric acid led to a reduction of cardiovascular risk factors via several pathways.